921 related articles for article (PubMed ID: 25686121)
1. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
Workenhe ST; Verschoor ML; Mossman KL
Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
[TBL] [Abstract][Full Text] [Related]
2. Integrating oncolytic viruses in combination cancer immunotherapy.
Bommareddy PK; Shettigar M; Kaufman HL
Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
[TBL] [Abstract][Full Text] [Related]
3. Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.
van Vloten JP; Workenhe ST; Wootton SK; Mossman KL; Bridle BW
J Immunol; 2018 Jan; 200(2):450-458. PubMed ID: 29311387
[TBL] [Abstract][Full Text] [Related]
4. Virotherapy: From single agents to combinatorial treatments.
Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Immunotherapy for Treatment of Cancer.
Tsun A; Miao XN; Wang CM; Yu DC
Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
[TBL] [Abstract][Full Text] [Related]
6. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
7. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Immunotherapy.
Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virus immunotherapy: future prospects for oncology.
Raja J; Ludwig JM; Gettinger SN; Schalper KA; Kim HS
J Immunother Cancer; 2018 Dec; 6(1):140. PubMed ID: 30514385
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic viruses and immunity.
Chaurasiya S; Chen NG; Fong Y
Curr Opin Immunol; 2018 Apr; 51():83-90. PubMed ID: 29550660
[TBL] [Abstract][Full Text] [Related]
12. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
Tian Y; Xie D; Yang L
Signal Transduct Target Ther; 2022 Apr; 7(1):117. PubMed ID: 35387984
[TBL] [Abstract][Full Text] [Related]
13. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?
Zhang S; Rabkin SD
Expert Opin Drug Discov; 2021 Apr; 16(4):391-410. PubMed ID: 33232188
[No Abstract] [Full Text] [Related]
14. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
[TBL] [Abstract][Full Text] [Related]
15. SnapShot: Cancer Immunotherapy with Oncolytic Viruses.
Gujar S; Bell J; Diallo JS
Cell; 2019 Feb; 176(5):1240-1240.e1. PubMed ID: 30794777
[TBL] [Abstract][Full Text] [Related]
16. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
[TBL] [Abstract][Full Text] [Related]
17. Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus.
Farrera-Sal M; Moya-Borrego L; Bazan-Peregrino M; Alemany R
Clin Cancer Res; 2021 Jun; 27(11):2979-2988. PubMed ID: 33526422
[TBL] [Abstract][Full Text] [Related]
18. Development of oncolytic virotherapy: from genetic modification to combination therapy.
Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic viruses and their application to cancer immunotherapy.
Chiocca EA; Rabkin SD
Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
